{"id":"W2802931074","doi":"10.1111/bjd.16736","title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada); Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Dermatology; Secukinumab; Pathology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004373871,0.0002429336,0.002199208,0.0004256433,0.0001167359,0.0000149548,0.0002167404,0.0002319432,0.00009858483],"category_scores_gemma":[0.0001899553,0.0002034481,0.0001694495,0.0002231105,0.000328915,0.0001485258,0.00006510103,0.000224359,0.000006293742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002780251,"about_ca_system_score_gemma":0.0001383815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000137295,"about_ca_topic_score_gemma":0.0003473563,"domain_scores_codex":[0.9969823,0.0009197131,0.001416378,0.000251331,0.0001060959,0.0003241277],"domain_scores_gemma":[0.9978333,0.0005613726,0.0008770505,0.000166066,0.0005008426,0.00006144588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9615956,0.004258026,0.008766706,0.00001916035,0.002346388,0.0003259896,0.00175667,0.0000159535,0.0002091608,0.00001865977,0.00009383186,0.02059385],"study_design_scores_gemma":[0.976483,0.002462166,0.01251474,0.0001503422,0.0008517973,0.004493492,0.0004996541,0.000005451336,0.002289056,0.00002316289,0.00003553081,0.0001916047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99529,0.00211039,0.0001209119,0.00004441042,0.0003392835,0.00188948,0.00005603936,0.000007314239,0.0001421737],"genre_scores_gemma":[0.9995444,0.0001489596,0.0001477232,0.00001932266,0.00002746643,0.00004350344,0.00001773587,0.00001944373,0.00003138731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02040225,"threshold_uncertainty_score":0.8296375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01209403580415269,"score_gpt":0.2528384543173931,"score_spread":0.2407444185132404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}